Catalyst Wire Dossier Catalyst Wire Dossier

Dato-DXd

datopotamab deruxtecan · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for Dato-DXd, covering 2025-06-13 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations [Phase 3]

See pricing